2seventy Extends Its Cash Runway Into 2025; Could Abecma Receive a ≥3L MM Approval Between 2023 – 2024? 2seventy Q4 2021 Earnings Summary

On Tuesday, March 22, 2seventy bio released their Q4 2021 results (press release) highlighting their extended cash runway into 2025 and Abecma’s (BCMA CAR-T) potential FDA approval in ≥3L MM between 2023 – 2024. Of note, no major updates were provided for other pipeline assets. Below, Celltelligence provides insights on how 2seventy could leverage their extended cash runway, while comparing Abecma’s potential approval in ≥3L MM with key competitor Carvykti (JNJ / Legend’s BCMA CAR-T).

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.